

BRIAN SANDOVAL  
Governor



RICHARD WHITLEY, MS  
Director

MARTA JENSEN  
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 East William Street, Suite 101  
Carson City, Nevada 89701  
Telephone (775) 684-3676 • Fax (775) 687-3893  
<http://dhcfp.nv.gov>

## NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

### AGENDA

**Date of Posting:** January 2, 2017

**Date of Revision:** January 5, 2018

**Date of Meeting:** Thursday, January 25, 2018 at 5:15 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP), Drug Use Review (DUR) Board

**Place of Meeting:** Hyatt Place Reno – Tahoe Airport  
1790 E. Plumb Lane  
Reno, NV 89502  
Phone: (775) 826-2500

**Webinar Registration:** <https://optum.webex.com/optum/onstage/g.php?MTID=e99bcf29e25e940176440dc3f0bbfad9c>

Or go to [www.webex.com](http://www.webex.com) and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Event Number:** 646 593 142

Click “Join Now”

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

**A password should not be necessary, but if asked, use:  
Medicaid**

**For Audio Only:**

**Phone: (763) 957-6300**

**Event: 646 593 142**

## **AGENDA**

- 1. Call to Order and Roll Call**
- 2. Public Comment on Any Matter on the Agenda**
- 3. Administrative**
  - a. **For Possible Action:** Review and Approve Meeting Minutes from October 19, 2017.
  - b. Status Update by the DHCFP.
  - c. **For Possible Action:** Review and Approve updated DUR Bylaws.
- 4. Clinical Presentations**
  - a. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for deutetrabenazine (Austedo®).
    - i. Public comment on proposed clinical prior authorization criteria.
    - ii. Presentation of utilization and clinical information.
    - iii. Discussion by Board and review of utilization data.
    - iv. Proposed adoption of updated prior authorization criteria.
  - b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for betrixaban (Bevyxxa®).
    - i. Public comment on proposed clinical prior authorization criteria.
    - ii. Presentation of utilization and clinical information.
    - iii. Discussion by Board and review of utilization data.
    - iv. Proposed adoption of updated prior authorization criteria.
  - c. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for belimumab (Benlysta®).
    - i. Public comment on proposed clinical prior authorization criteria.
    - ii. Presentation of utilization and clinical information.
    - iii. Discussion by Board and review of utilization data.

- iv. Proposed adoption of updated prior authorization criteria.
- d. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Hepatitis C Direct-Acting Antiviral agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Immunomodulator agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Opioid-Induced Constipation Agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.

**5. Public Comment on any DUR Board Requested Report**

**6. DUR Board Requested Reports**

- a. Utilization of medications with Orphan Designation.
  - i. Discussion by the Board and review of utilization data.
  - ii. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- b. Opioid utilization – Members under age 18 years.
  - i. Discussion by the Board and review of utilization data.
  - ii. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- c. Opioid Utilization – Top prescriber and member.
  - i. Discussion by the Board and review of utilization data.

- ii. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

**7. Public Comment on any Standard DUR Report**

**8. Standard DUR Reports**

- a. Review of Prescribing/Program Trends.
  - i. Top 10 Therapeutic Classes for Q1 2011, Q2 2017 and Q3 2017 (by Payment and by Claims).
  - ii. Top 50 Drugs of Q1 2011, Q2 2017 and Q3 2017 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
  - i. Review of Q1 2011, Q2 2017 and Q3 2017.
  - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
  - i. Status of previous quarter.
  - ii. Status of current quarter.
  - iii. Review and discussion of responses.

**9. Closing Discussion**

- a. Public comments on any subject.
- b. Date and location of the next meeting.
  - i. Discussion of the time of the next meeting.
- c. Adjournment.

**PLEASE NOTE:** Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov> and <http://notice.nv.gov>, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library;

January 4, 2018

Page 5

**Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Robyn Heddy at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.**

**All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.**

**Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at [cmclach@dhecp.nv.gov](mailto:cmclach@dhecp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Colleen McLachlan at (775) 684-3722.**